Fiche centre
Advent Health Orlando
Orlando — United States
Essais liés6clinical trials
VilleOrlandolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05739383
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| OPTIMIZER® Integra CCM-D System (Treatment Arm) | Maladie coronarienne | Non applicable | NCT05855135 | INTEGRA-D — Assessment of Combined CCM and ICD Device in HFrEF | ACTIVE_NOT_RECRUITING |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| Vivistim System | Accident vasculaire cérébral | À vérifier | NCT05301140 | Vivistim Registry for Paired VNS Therapy (GRASP) | RECRUITING |
| PROACTION: — Investigations of Reproductive Cancers in Women | Cancer | À vérifier | NCT06527157 | PROACTION: — Investigations of Reproductive Cancers in Women | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |